Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday. The post Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers appeared first on Investor’s Business Daily.
Amgen and AstraZeneca’s drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S. The post Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent? appeared first on Investor’s Business Daily.
Revolution Medicines won FDA approval Wednesday for the pancreatic cancer treatment that once caused its stock to skyrocket. The post FDA Approves ‘Unprecedented’ Pancreatic Cancer Drug appeared first on Investor’s Business Daily.
Spyre Therapeutics took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing. The post Spyre Plunges, While This Setback Isn’t Shaking Analysts appeared first on Investor’s Business Daily.
Jazz stock bounced off its buy zone Tuesday after the FDA approved its drug, Ziihera, to treat a form of stomach cancer. The post Jazz Sparks On Its New Plan To Take On Roche; Hint: It’s In Cancer appeared first…
State Street SPDR S&P Biotech ETF is hovering above a buy point after breaking out. The post Analysts See Drastic Change For This Particular Part Of Healthcare appeared first on Investor’s Business Daily.
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average. The post TGTX Stock Outperforms 95% of Stocks. Here’s Why. appeared first on Investor’s Business Daily.
Travere Therapeutics is Friday’s IBD Stock Of The Day. As the Filspari story gets “sweeter,” shares are clearing a fresh buy point. The post IBD Stock Of The Day, Travere Therapeutics, Tests Another Breakout. Can The Stock Get Any ‘Sweeter?’…
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months. The post Three Biotech Stocks Stick Out With Their Stellar Charts appeared first on Investor’s Business Daily.
Moderna stock could catch the eye of investors looking for the next big AI play, Revere Asset Management’s Don Vandenbord says. The post Moderna Stock Is Just The Start: Why AI-Focused Money Might Flow Into Biotech appeared first on Investor’s…
